Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Single-arm, Open-label, Multicenter Study of Enfortumab vedotin (ASG-22CE) for Treatment of Subjects With Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy.

    Summary
    EudraCT number
    2017-003479-78
    Trial protocol
    DE   ES   NL   IT  
    Global end of trial date
    28 Jul 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    07 Aug 2024
    First version publication date
    07 Aug 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    SGN22E-001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03219333
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Seagen Inc
    Sponsor organisation address
    21823 30th Drive S.E.,, Bothell, United States, 98021
    Public contact
    Chief Medical Officer, Seagen Inc.,, 1 8554732436, medinfo@seagen.com
    Scientific contact
    Chief Medical Officer, Seagen Inc, 1 8554732436, medinfo@seagen.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 Jan 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Jul 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To determine the antitumor activity of single-agent enfortumab vedotin as measured by confirmed Objective Response Rate (ORR) in participants with locally advanced or metastatic urothelial cancer who have previously received systemic therapy with a CPI and either previously received platinum-containing chemotherapy or are platinum-naïve and cisplatin ineligible.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    08 Oct 2017
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Efficacy, Safety
    Long term follow-up duration
    2 Years
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 178
    Country: Number of subjects enrolled
    Netherlands: 5
    Country: Number of subjects enrolled
    France: 4
    Country: Number of subjects enrolled
    Spain: 1
    Country: Number of subjects enrolled
    Italy: 4
    Country: Number of subjects enrolled
    Japan: 14
    Country: Number of subjects enrolled
    Korea, Republic of: 13
    Worldwide total number of subjects
    219
    EEA total number of subjects
    14
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    61
    From 65 to 84 years
    146
    85 years and over
    12

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Eligible participants with locally advanced or metastatic urothelial cancer who have previously received systemic therapy with a programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor and met inclusion criteria and none of the exclusion criteria were enrolled in the study.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Enfortumab vedotin - Cohort 1
    Arm description
    Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
    Arm type
    Experimental

    Investigational medicinal product name
    Enfortumab vedotin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1.25 mg/kg was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Arm title
    Enfortumab vedotin - Cohort 2
    Arm description
    Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
    Arm type
    Experimental

    Investigational medicinal product name
    Enfortumab vedotin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1.25 mg/kg was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Number of subjects in period 1
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Started
    128
    91
    Treated
    125
    89
    Completed
    0
    0
    Not completed
    128
    91
         Consent withdrawn by subject
    9
    4
         Death
    104
    72
         Unspecified
    2
    2
         Study closed 2023,major completed 5year follow-up
    12
    12
         Lost to follow-up
    1
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Enfortumab vedotin - Cohort 1
    Reporting group description
    Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Reporting group title
    Enfortumab vedotin - Cohort 2
    Reporting group description
    Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Reporting group values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2 Total
    Number of subjects
    128 91 219
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    45 16 61
        From 65-84 years
    83 63 146
        85 years and over
    0 12 12
    Age Continuous
    Units: Years
        median (full range (min-max))
    69.0 (40 to 84) 75.0 (49 to 91) -
    Sex: Female, Male
    Units: Participants
        Female
    38 23 61
        Male
    90 68 158
    Race Customised
    Units: Subjects
        Asian
    12 20 32
        Black or African American
    2 0 2
        White
    108 64 172
        Other
    1 0 1
        Not Reportable
    5 7 12
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    5 1 6
        Not Hispanic or Latino
    121 85 206
        Unknown or Not Reported
    2 5 7
    Region of Enrollment
    Units: Subjects
        North America
    119 59 178
        Europe
    0 14 14
        Asia
    9 18 27
    Eastern Cooperative Oncology Group (ECOG) Performance Status
    ECOG performance status was used to assess participants disease progression, and ability to carry out daily living activities. 0=Normal activity; 1=Symptoms but ambulatory; 2=In bed <50% of the time; 3= In bed >50% of the time; 4=100% bedridden; 5=Dead
    Units: Subjects
        ECOG: 0
    40 37 77
        ECOG: 1
    85 41 126
        ECOG: 2
    0 11 11
        Missing
    3 2 5

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Enfortumab vedotin - Cohort 1
    Reporting group description
    Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Reporting group title
    Enfortumab vedotin - Cohort 2
    Reporting group description
    Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Primary: Objective Response Rate (ORR) per Blinded Independent Central Review (BICR)

    Close Top of page
    End point title
    Objective Response Rate (ORR) per Blinded Independent Central Review (BICR) [1]
    End point description
    ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is defined as a >=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.
    End point type
    Primary
    End point timeframe
    Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive analysis was planned for this endpoint.
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Percentage of Participants
        number (confidence interval 95%)
    44 (35.1 to 53.2)
    51.7 (40.8 to 62.4)
    No statistical analyses for this end point

    Secondary: Progression-Free Survival (PFS) per BICR

    Close Top of page
    End point title
    Progression-Free Survival (PFS) per BICR
    End point description
    The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Months
        median (confidence interval 95%)
    5.8 (4.93 to 7.46)
    5.8 (5.03 to 8.28)
    No statistical analyses for this end point

    Secondary: ORR per Investigator Assessment

    Close Top of page
    End point title
    ORR per Investigator Assessment
    End point description
    ORR was defined as the percentage of participants with confirmed CR or PR according to RECIST 1.1. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is defined as a >=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Percentage of Participants
        number (confidence interval 95%)
    39 (30.6 to 48.3)
    50.6 (39.8 to 61.3)
    No statistical analyses for this end point

    Secondary: Duration of Objective Response (DOR) per BICR

    Close Top of page
    End point title
    Duration of Objective Response (DOR) per BICR
    End point description
    Time from first documentation of objective response(CR or PR that is subsequently confirmed) to first documentation of progressive disease(PD) or death due to any cause, whichever comes first.CR=disappearance of all target lesions, non-target lesions. Any pathological lymph nodes(whether target or non-target) reduction in short axis to <10 mm.PR = >=30% decrease in sum of diameters of target lesions,reference: baseline sum of diameters. PD=at least 20% increase in sum of diameters of target lesions, taking reference smallest sum on study(this includes baseline sum if that is smallest on study).In addition to relative increase of 20%, sum must demonstrate an absolute increase of at least 0.5 cm. Appearance of one or more new lesions=progression. DOR analyzed using Kaplan-Meier methodology. Full analysis set.‘99999’=Upper limit of 95%CI not estimated due to insufficient number of participants with events. Here, ‘Number of Participants Analyzed’=number of participants evaluable.
    End point type
    Secondary
    End point timeframe
    Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    55
    46
    Units: Months
        median (confidence interval 95%)
    7.6 (6.34 to 99999)
    10.9 (5.78 to 99999)
    No statistical analyses for this end point

    Secondary: DOR per Investigator Assessment

    Close Top of page
    End point title
    DOR per Investigator Assessment
    End point description
    CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is defined as a >=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. Full analysis set. ‘99999’=Upper limit of 95%CI not estimated due to insufficient number of participants with events. Here, ‘Number of Participants Analyzed’ signifies number of participants evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    49
    45
    Units: Months
        median (confidence interval 95%)
    7.9 (5.95 to 99999)
    10.7 (5.85 to 16.59)
    No statistical analyses for this end point

    Secondary: PFS per Investigator Assessment

    Close Top of page
    End point title
    PFS per Investigator Assessment
    End point description
    The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Months
        median (confidence interval 95%)
    5.8 (4.93 to 7.46)
    7.2 (5.42 to 7.69)
    No statistical analyses for this end point

    Secondary: Number of Participants with Treatment-Emergent Laboratory Abnormalities (Hematology)

    Close Top of page
    End point title
    Number of Participants with Treatment-Emergent Laboratory Abnormalities (Hematology)
    End point description
    A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based on National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening. Safety Analysis set. Here 'Number Analyzed' for each laboratory parameter is based on the number of participants who received at least one dose of enfortumab vedotin and have a baseline and post-baseline laboratory value.
    End point type
    Secondary
    End point timeframe
    The median duration of treatment was 4.60 months for Cohort 1 [range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [range: 0.3, 24.6 months]
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Participants
        Hemoglobin decreased (all grades)n=122,88
    52
    39
        Hemoglobin decreased (grade 3-4)n=122,88
    12
    4
        Leukocytes decreased (all grades)n=122,88
    33
    28
        Leukocytes decreased (grade 3-4)n=122,88
    5
    4
        Lymphocytes decreased (all grades)n=122,88
    55
    61
        Lymphocytes decreased (grade 3-4)n=122,88
    12
    13
        Lymphocytes increased (all grades)n=125,88
    0
    1
        Lymphocytes increased (grade 3-4)n=125,89
    0
    0
        Neutrophils decreased (all grades)n=122,88
    28
    27
        Neutrophils decreased (grade 3-4)n=122,88
    7
    8
        Platelets decreased (all grades)n=121,88
    39
    20
        Platelets decreased (grade 3-4)n=125,89
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Participants with Treatment-Emergent Laboratory Abnormalities (Serum Chemistry)

    Close Top of page
    End point title
    Number of Participants with Treatment-Emergent Laboratory Abnormalities (Serum Chemistry)
    End point description
    A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based NCI CTCAE version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening. Safety Analysis set. ‘99999’: Fasting glucose is required for CTCAE grading of hyperglycemia grade 1-2, not grade 3-4. Since fasting glucose was not required for this study, grade 1-2 (glucose-high) could not be determined. Only grade 3-4 was determined. Here 'Number Analyzed' for each laboratory parameter is based on the number of participants who received at least one dose of enfortumab vedotin and have a baseline and post-baseline laboratory value.
    End point type
    Secondary
    End point timeframe
    The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Participants
        Alanine aminotransferase increase(all G) n=122,88
    34
    26
        Alanine aminotransferase increase(G 3-4)n=122,89
    1
    0
        Albumin decreased (all G)n=122,88
    38
    16
        Albumin decreased (G 3-4)n=122,88
    1
    0
        Alkaline phosphatase increased (all G)n=122,88
    21
    12
        Alkaline phosphatase increased (G 3-4)n=122,88
    1
    0
        Aspartate aminotransferase increase(all G)n=121,88
    79
    52
        Aspartate aminotransferase increase(G 3-4)n=121,88
    3
    2
        Bilirubin increased (all G)n=122,88
    13
    5
        Bilirubin increased (G 3-4)n=122,89
    1
    0
        Calcium decreased (all G)n=122,88
    15
    7
        Calcium decreased (G 3-4)n=125,89
    0
    0
        Calcium increased (all G)n=122,88
    1
    7
        Calcium increased (G 3-4)n=125,88
    0
    3
        Creatinine increased (all G)n=122,88
    73
    46
        Creatinine increased (G 3-4)n=122,88
    2
    3
        Glucose decreased (all G)n=122,88
    32
    26
        Glucose decreased (G 3-4)n=125,89
    0
    0
        Glucose increased (all G)n=125,89
    99999
    99999
        Glucose increased (G 3-4)n=125,89
    10
    11
        Phosphate decreased (all G)n=122,88
    42
    22
        Phosphate decreased (G 3-4)n=122,88
    12
    6
        Potassium decreased (all G)n=122,88
    25
    11
        Potassium decreased (G 3-4)n=122,88
    2
    1
        Potassium increased (all G)n=122,88
    13
    17
        Potassium increased (G 3-4)n=125,88
    0
    5
        Sodium decreased (all G)n=122,88
    54
    28
        Sodium decreased (G 3-4)n=122,88
    10
    6
        Sodium increased (all G)n=122,88
    2
    1
        Sodium increased (G 3-4)n=125,89
    0
    0
        Urate increased (all G)n=122,88
    32
    38
        Urate increased (grade 3-4)n=122,88
    8
    8
        Amylase increased (all grades)n=122,88
    20
    18
        Amylase increased (grade 3-4)n=122,88
    1
    3
        Lipase increased (all grades)n=122,88
    37
    32
        Lipase increased (grade 3-4)n=122,88
    12
    10
    No statistical analyses for this end point

    Secondary: Incidence of Antitherapeutic Antibody (ATA)

    Close Top of page
    End point title
    Incidence of Antitherapeutic Antibody (ATA)
    End point description
    Participants who were tested positive for ATA at any time post-baseline were considered to be transiently positive or persistently positive if >=2 consecutive samples were confirmed as positive. Safety Analysis Set: Participants who received at least one dose of enfortumab vedotin. Here, 'Overall Number of Participants Analyzed' signifies ATA subset (participants with a baseline and at least one post-baseline sample). Here, 'Number Analyzed' signifies participants evaluable for specified rows.
    End point type
    Secondary
    End point timeframe
    The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    114
    81
    Units: Participants
        Baseline Negative|Negative post-baseline(n=112,80)
    109
    76
        Baseline Positive|Negative post-baseline(n=112,80)
    1
    1
        Baseline Negative|Transiently P post basl(n=112,80
    2
    3
        Baseline Positive|Transiently P post-basl(n=2,1)
    1
    0
        Baseline Negative|Persistently P post-basl(n=2,1)
    1
    1
        Baseline Positive|Persistently P post-basl(n=2,1)
    0
    0
    No statistical analyses for this end point

    Secondary: DCR16 per Investigator Assessment

    Close Top of page
    End point title
    DCR16 per Investigator Assessment
    End point description
    Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR = disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR = >=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD = at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. Appearance of one or more new lesions = considered progression. SD = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    Up to Week 16
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Percentage of Participants
        number (confidence interval 95%)
    55 (46.0 to 64.1)
    64.0 (53.2 to 73.9)
    No statistical analyses for this end point

    Secondary: Disease Control Rate at 16 weeks (DCR16) per BICR

    Close Top of page
    End point title
    Disease Control Rate at 16 weeks (DCR16) per BICR
    End point description
    Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is defined as a >=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    Up to Week 16
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Percentage of Participants
        number (confidence interval 95%)
    50 (41.3 to 59.5)
    58.4 (47.5 to 68.8)
    No statistical analyses for this end point

    Secondary: Overall Survival (OS) at Time of Primary Analysis

    Close Top of page
    End point title
    Overall Survival (OS) at Time of Primary Analysis
    End point description
    OS is defined as the time from first dose of enfortumab vedotin to death from any cause. Full analysis set: included all enrolled participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    Cohort 1 median follow-up time: 28.4 months [range 0.49, 32.62]; Cohort 2 median follow up time: 13.4 months [range 0.33 to 29.27]
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Months
        median (confidence interval 95%)
    12.4 (9.46 to 15.57)
    14.7 (10.51 to 18.20)
    No statistical analyses for this end point

    Secondary: Number of Participants with Adverse Events (AEs) at Time of Primary Analysis

    Close Top of page
    End point title
    Number of Participants with Adverse Events (AEs) at Time of Primary Analysis
    End point description
    AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event(TEAE)=newly occurring/worsening AE after first dose, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE,G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity;congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator. Safety Analysis Set: includes all participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    The median duration of treatment was 4.60 months for Cohort 1 [range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [range: 0.3, 24.6 months]
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Participants
        Any treatment-emergent AEs (TEAEs)
    125
    89
        Treatment-related TEAEs
    117
    86
        Any grade 3-5 TEAEs
    93
    62
        Treatment-related grade 3-5 TEAEs
    70
    49
        Any serious TEAEs
    59
    35
        Treatment-related serious TEAEs
    24
    15
        Any TEAEs leading to treatment discontinuation
    21
    18
        TR TEAEs lead to treatment discontinuation
    15
    14
        Any TEAEs leading to death
    7
    8
        Treatment-related TEAEs leading to death
    0
    3
    No statistical analyses for this end point

    Secondary: Pharmacokinetics (PK) Parameter for Enfortumab Vedotin: Maximum Concentration (Cmax) (Serum)

    Close Top of page
    End point title
    Pharmacokinetics (PK) Parameter for Enfortumab Vedotin: Maximum Concentration (Cmax) (Serum)
    End point description
    Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    120
    87
    Units: Microgram per milliliter (µg/mL)
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 (n=120,87)
    26.6 ( 28.5 )
    23.9 ( 24.4 )
        Cycle 1, Day 15 (n=93,64)
    26.0 ( 28.3 )
    21.7 ( 29.7 )
        Cycle 2, Day 1 (n=105,73)
    24.5 ( 31.4 )
    22.0 ( 24.5 )
        Cycle 2, Day 15 (n=95,62)
    26.3 ( 25.2 )
    20.7 ( 27.4 )
    No statistical analyses for this end point

    Secondary: PK Parameter for Enfortumab Vedotin: Time to Maximum Concentration (Tmax) (Serum)

    Close Top of page
    End point title
    PK Parameter for Enfortumab Vedotin: Time to Maximum Concentration (Tmax) (Serum)
    End point description
    Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    120
    87
    Units: Days
    median (full range (min-max))
        Cycle 1, Day 1 (n=119,87)
    0.0278 (0.010 to 0.052)
    0.0264 (0.021 to 0.088)
        Cycle 1, Day 15 (n=92,63)
    0.0285 (0.014 to 0.054)
    0.0264 (0.014 to 0.084)
        Cycle 2, Day 1 (n=104,73)
    0.0264 (0.011 to 0.042)
    0.0264 (0.015 to 0.074)
        Cycle 2, Day 15 (n=94,62)
    0.0285 (0.020 to 0.115)
    0.0257 (0.010 to 0.047)
    No statistical analyses for this end point

    Secondary: PK Parameter for Enfortumab Vedotin: Area Under Concentration-Time Curve (AUC) (Serum)

    Close Top of page
    End point title
    PK Parameter for Enfortumab Vedotin: Area Under Concentration-Time Curve (AUC) (Serum)
    End point description
    AUC was derived from the PK blood samples collected. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    120
    87
    Units: Day*microgram per milliliter
    geometric mean (geometric coefficient of variation)
        7-day post-inf AUC(AUC(d0-7))-Cycle 1,D1 n=115,85
    34.6 ( 34.0 )
    33.5 ( 41.4 )
        AUC(d0-7) - Cycle 1, Day 15 n=88,63
    31.3 ( 43.8 )
    26.3 ( 46.0 )
        AUC(d0-7) - Cycle 2, Day 1 n=104,72
    36.4 ( 36.7 )
    32.0 ( 30.0 )
        AUC(d0-7) - Cycle 2, Day 15 n=88,56
    35.9 ( 41.2 )
    27.8 ( 35.8 )
        14-day post-inf AUC(AUC(d0-14))Cycle1,D15 n=85,59
    34.7 ( 44.7 )
    30.9 ( 47.5 )
        AUC(d0-14) - Cycle 2, Day 15 n=82,60
    41.2 ( 40.4 )
    33.1 ( 36.6 )
    No statistical analyses for this end point

    Secondary: PK Parameter for Free Monomethyl Auristatin E (MMAE): Cmax (Plasma)

    Close Top of page
    End point title
    PK Parameter for Free Monomethyl Auristatin E (MMAE): Cmax (Plasma)
    End point description
    Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, MMAE or Tab concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Overall Number of Participants Analyzed’=number of participants evaluable for this outcome measure. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    117
    84
    Units: Nanogram per milliliter
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 n=117,84
    3.1 ( 67.0 )
    2.6 ( 57.8 )
        Cycle 1, Day 15 n=93,64
    3.9 ( 64.8 )
    3.5 ( 51.8 )
        Cycle 2, Day 1 n=106,72
    2.4 ( 57.4 )
    2.2 ( 60.8 )
        Cycle 2, Day 15 n=90,62
    3.0 ( 64.8 )
    2.9 ( 59.9 )
    No statistical analyses for this end point

    Secondary: PK Parameter for Free MMAE: Tmax (Plasma)

    Close Top of page
    End point title
    PK Parameter for Free MMAE: Tmax (Plasma)
    End point description
    Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, MMAE or Tab concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Overall Number of Participants Analyzed’=number of participants evaluable for this outcome measure. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    117
    84
    Units: Days
    median (full range (min-max))
        Cycle 1, Day 1 n=117,84
    1.9 (1 to 5)
    1.9 (1 to 4)
        Cycle 1, Day 15 n=93,64
    2.0 (1 to 11)
    1.9 (1 to 9)
        Cycle 2, Day 1 n=106,72
    2.0 (1 to 5)
    1.8 (1 to 5)
        Cycle 2, Day 15 n=90,62
    1.9 (1 to 9)
    1.9 (1 to 10)
    No statistical analyses for this end point

    Secondary: PK Parameter for Free MMAE: AUC (Plasma)

    Close Top of page
    End point title
    PK Parameter for Free MMAE: AUC (Plasma)
    End point description
    AUC was derived from the PK blood samples collected. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, MMAE or Tab concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Overall Number of Participants Analyzed’=number of participants evaluable for this outcome measure. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    117
    84
    Units: Day*nanogram per milliliter
    geometric mean (geometric coefficient of variation)
        7-day post-inf AUC(AUC(d0-7))-Cycle1,Day1 n=115,84
    14.1 ( 81.7 )
    13.0 ( 64.1 )
        AUC(d0-7) - Cycle 1, Day 15 n=88,66
    19.1 ( 79.1 )
    18.1 ( 65.0 )
        AUC(d0-7) - Cycle 2, Day 1 n=104,72
    11.3 ( 58.0 )
    10.6 ( 65.0 )
        AUC(d0-7) - Cycle 2, Day 15 n=88,57
    14.9 ( 64.7 )
    15.3 ( 60.2 )
        14-day post-inf AUC(AUC(d0-14))-Cycle1,D15 n=91,62
    25.9 ( 74.7 )
    22.6 ( 76.4 )
        AUC(d0-14) - Cycle 2, Day 15 n=84,63
    19.1 ( 61.2 )
    21.3 ( 65.0 )
    No statistical analyses for this end point

    Secondary: PK Parameter for Total Antibody (TAb): Cmax (Serum)

    Close Top of page
    End point title
    PK Parameter for Total Antibody (TAb): Cmax (Serum)
    End point description
    Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    120
    87
    Units: Microgram per milliliter
    geometric mean (geometric coefficient of variation)
        Cycle 1, Day 1 n=120,87
    26.6 ( 30.4 )
    26.4 ( 23.4 )
        Cycle 1, Day 15 n=93,64
    30.9 ( 22.9 )
    27.3 ( 25.7 )
        Cycle 2, Day 1 n=105,74
    26.2 ( 30.5 )
    26.3 ( 23.8 )
        Cycle 2, Day 15 n=95,62
    30.2 ( 22.7 )
    27.1 ( 28.2 )
    No statistical analyses for this end point

    Secondary: PK Parameter for TAb: Tmax (Serum)

    Close Top of page
    End point title
    PK Parameter for TAb: Tmax (Serum)
    End point description
    Tmax was derived from the PK blood samples collected. Time of maximum concentration corresponds to the end of infusion sample time. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    120
    87
    Units: Days
    median (full range (min-max))
        Cycle 1, Day 1 n=119,87
    0.0278 (0.010 to 0.052)
    0.0264 (0.021 to 0.088)
        Cycle 1, Day 15 n=92,63
    0.0285 (0.014 to 0.054)
    0.0264 (0.014 to 0.084)
        Cycle 2, Day 1 n=104,74
    0.0264 (0.011 to 0.042)
    0.0264 (0.015 to 0.074)
        Cycle 2, Day 15 n=94,62
    0.0285 (0.020 to 0.115)
    0.0257 (0.010 to 0.047)
    No statistical analyses for this end point

    Secondary: PK Parameter for TAb: AUC (Serum)

    Close Top of page
    End point title
    PK Parameter for TAb: AUC (Serum)
    End point description
    AUC was derived from the PK blood samples collected. PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, monomethyl auristatin E (MMAE) or total antibody (Tab) concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, ‘Number Analyzed’= participants evaluable at specified timepoints.
    End point type
    Secondary
    End point timeframe
    AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    120
    87
    Units: Day*microgram per milliliter
    geometric mean (geometric coefficient of variation)
        7-day post-inf AUC(AUC(d0-7)) - Cycle1,D1 n=115,85
    63.4 ( 33.6 )
    66.8 ( 34.3 )
        AUC(d0-7) - Cycle 1, Day 15 n=88,63
    77.6 ( 35.2 )
    72.3 ( 37.9 )
        AUC(d0-7) - Cycle 2, Day 1 n=104,72
    73.2 ( 33.5 )
    72.9 ( 26.4 )
        AUC(d0-7) - Cycle 2, Day 15 n=88,56
    87.9 ( 30.6 )
    81.0 ( 30.9 )
        14-day post-inf AUC(AUC(d0-14))-Cycle1,D15 n=93,62
    98.1 ( 38.8 )
    91.1 ( 40.3 )
        AUC(d0-14) - Cycle 2, Day 15 n=84,62
    113.0 ( 33.8 )
    109.7 ( 41.5 )
    No statistical analyses for this end point

    Secondary: Number of Subjects With Adverse Events (AEs): Final Analysis

    Close Top of page
    End point title
    Number of Subjects With Adverse Events (AEs): Final Analysis
    End point description
    AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event(TEAE)=newly occurring/worsening AE after first dose, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE,G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity;congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator. Safety Analysis Set: includes all participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    Cohort 1: median treatment duration time: 4.60 months (range 0.5, 43.0); Cohort 2: median treatment duration time: 5.98 months (range 0.3 to 25.8)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Participants
        Any treatment-emergent AEs (TEAEs)
    125
    89
        Treatment-related TEAEs
    117
    86
        Any grade 3-5 TEAEs
    93
    62
        Treatment-related grade 3-5 TEAEs
    70
    49
        Any serious TEAEs
    59
    35
        Treatment-related serious TEAEs
    24
    15
        Any TEAEs leading to treatment discontinuation
    22
    21
        TR TEAEs leading to treatment discontinuation
    16
    17
        Any TEAEs leading to death
    7
    8
        Treatment-related TEAEs leading to death
    0
    3
    No statistical analyses for this end point

    Secondary: Overall Survival (OS): Final Analysis

    Close Top of page
    End point title
    Overall Survival (OS): Final Analysis
    End point description
    OS is defined as the time from first dose of enfortumab vedotin to death from any cause. Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.
    End point type
    Secondary
    End point timeframe
    Cohort 1: median follow-up: 61.0 months (range 59.63, 62.36); Cohort 2: median follow-up time: 45.8 months (range 44.91 to 48.95)
    End point values
    Enfortumab vedotin - Cohort 1 Enfortumab vedotin - Cohort 2
    Number of subjects analysed
    125
    89
    Units: Months
        median (confidence interval 95%)
    12.4 (9.46 to 15.57)
    15.6 (11.24 to 20.37)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Cohort 1: maximum up to 43.0 months of treatment; Cohort 2: maximum up to 25.8 months of treatment
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    v26.0
    Reporting groups
    Reporting group title
    Enfortumab vedotin - Cohort 2
    Reporting group description
    Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Reporting group title
    Enfortumab vedotin - Cohort 1
    Reporting group description
    Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Serious adverse events
    Enfortumab vedotin - Cohort 2 Enfortumab vedotin - Cohort 1
    Total subjects affected by serious adverse events
         subjects affected / exposed
    35 / 89 (39.33%)
    59 / 125 (47.20%)
         number of deaths (all causes)
    72
    104
         number of deaths resulting from adverse events
    8
    7
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Squamous cell carcinoma of skin
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cancer pain
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colon cancer
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Transitional cell carcinoma metastatic
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    3 / 89 (3.37%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 3
    0 / 2
    Transitional cell carcinoma
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Vascular disorders
    Embolism
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypertension
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotension
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    2 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aortic stenosis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Deep vein thrombosis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Shock
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Chills
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthenia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fatigue
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Incarcerated hernia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infusion site extravasation
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Multiple organ dysfunction syndrome
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Non-cardiac chest pain
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyrexia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acute respiratory failure
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Aspiration
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chronic obstructive pulmonary disease
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cough
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dyspnoea
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    4 / 125 (3.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypoxia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Interstitial lung disease
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural effusion
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonitis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Delirium
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Confusional state
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Amylase increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic enzyme increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lipase increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neutrophil count decreased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urine output decreased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    White blood cell count decreased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Compression fracture
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fall
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wound
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Myocardial infarction
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorder
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Atrial thrombosis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial fibrillation
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute myocardial infarction
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Spinal cord compression
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral motor neuropathy
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Paraplegia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Encephalopathy
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Demyelinating polyneuropathy
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Neutropenia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    2 / 2
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Febrile neutropenia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    5 / 125 (4.00%)
         occurrences causally related to treatment / all
    1 / 1
    5 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Cataract
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Nausea
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    1 / 2
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Odynophagia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Large intestinal obstruction
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Enterocolitis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    3 / 89 (3.37%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    2 / 3
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colitis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small intestinal obstruction
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    2 / 2
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Stomatitis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Bile duct stone
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Rash vesicular
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rash maculo-papular
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rash
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drug eruption
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dermatitis bullous
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Stevens-Johnson syndrome
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    4 / 125 (3.20%)
         occurrences causally related to treatment / all
    3 / 10
    1 / 4
         deaths causally related to treatment / all
    1 / 2
    0 / 0
    Urinary tract obstruction
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ureterolithiasis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal impairment
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematuria
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    Adrenal insufficiency
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bone pain
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Muscular weakness
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myositis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    3 / 89 (3.37%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bacteraemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Kidney infection
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Joint abscess
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infection
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device related infection
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cellulitis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    6 / 125 (4.80%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia aspiration
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Pneumonia bacterial
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    4 / 89 (4.49%)
    4 / 125 (3.20%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 4
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Urinary tract infection
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    3 / 89 (3.37%)
    6 / 125 (4.80%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection staphylococcal
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urosepsis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Metabolic acidosis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Hypomagnesaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypoglycaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperuricaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    0 / 89 (0.00%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperkalaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    0 / 125 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperglycaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    2 / 125 (1.60%)
         occurrences causally related to treatment / all
    2 / 2
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dehydration
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    1 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Decreased appetite
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    1 / 125 (0.80%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyponatraemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    3 / 125 (2.40%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Enfortumab vedotin - Cohort 2 Enfortumab vedotin - Cohort 1
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    88 / 89 (98.88%)
    123 / 125 (98.40%)
    Vascular disorders
    Hypertension
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    4 / 89 (4.49%)
    7 / 125 (5.60%)
         occurrences all number
    5
    12
    Hypotension
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    4 / 89 (4.49%)
    9 / 125 (7.20%)
         occurrences all number
    5
    10
    General disorders and administration site conditions
    Asthenia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    7 / 89 (7.87%)
    7 / 125 (5.60%)
         occurrences all number
    15
    7
    Chills
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    7 / 89 (7.87%)
    5 / 125 (4.00%)
         occurrences all number
    8
    9
    Fatigue
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    40 / 89 (44.94%)
    66 / 125 (52.80%)
         occurrences all number
    41
    71
    Gait disturbance
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    7 / 125 (5.60%)
         occurrences all number
    9
    7
    Malaise
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    10 / 125 (8.00%)
         occurrences all number
    3
    10
    Oedema peripheral
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    20 / 89 (22.47%)
    31 / 125 (24.80%)
         occurrences all number
    22
    45
    Pyrexia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    14 / 89 (15.73%)
    15 / 125 (12.00%)
         occurrences all number
    16
    17
    Respiratory, thoracic and mediastinal disorders
    Rhinorrhoea
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    7 / 125 (5.60%)
         occurrences all number
    9
    8
    Dyspnoea
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    14 / 89 (15.73%)
    15 / 125 (12.00%)
         occurrences all number
    16
    19
    Dysphonia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    7 / 125 (5.60%)
         occurrences all number
    5
    7
    Cough
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    12 / 89 (13.48%)
    20 / 125 (16.00%)
         occurrences all number
    15
    25
    Psychiatric disorders
    Anxiety
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    4 / 125 (3.20%)
         occurrences all number
    5
    5
    Insomnia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    13 / 89 (14.61%)
    18 / 125 (14.40%)
         occurrences all number
    13
    18
    Investigations
    Amylase increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    15 / 89 (16.85%)
    13 / 125 (10.40%)
         occurrences all number
    19
    17
    Aspartate aminotransferase increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    11 / 89 (12.36%)
    19 / 125 (15.20%)
         occurrences all number
    15
    27
    Blood alkaline phosphatase increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    7 / 125 (5.60%)
         occurrences all number
    1
    7
    Blood creatinine increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    11 / 125 (8.80%)
         occurrences all number
    10
    17
    Lipase increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    16 / 125 (12.80%)
         occurrences all number
    15
    27
    Lymphocyte count decreased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    9 / 125 (7.20%)
         occurrences all number
    5
    9
    Weight decreased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    31 / 89 (34.83%)
    40 / 125 (32.00%)
         occurrences all number
    33
    41
    Alanine aminotransferase increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    15 / 125 (12.00%)
         occurrences all number
    11
    16
    Injury, poisoning and procedural complications
    Fall
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    14 / 125 (11.20%)
         occurrences all number
    12
    18
    Infusion related reaction
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    4 / 125 (3.20%)
         occurrences all number
    6
    5
    Cardiac disorders
    Palpitations
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    1 / 125 (0.80%)
         occurrences all number
    7
    1
    Tachycardia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    1 / 89 (1.12%)
    9 / 125 (7.20%)
         occurrences all number
    1
    10
    Nervous system disorders
    Dizziness
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    10 / 89 (11.24%)
    20 / 125 (16.00%)
         occurrences all number
    12
    23
    Dysgeusia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    27 / 89 (30.34%)
    49 / 125 (39.20%)
         occurrences all number
    28
    53
    Headache
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    6 / 125 (4.80%)
         occurrences all number
    6
    6
    Paraesthesia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    4 / 125 (3.20%)
         occurrences all number
    7
    4
    Peripheral motor neuropathy
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    14 / 125 (11.20%)
         occurrences all number
    9
    16
    Peripheral sensory neuropathy
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    47 / 89 (52.81%)
    54 / 125 (43.20%)
         occurrences all number
    53
    59
    Blood and lymphatic system disorders
    Anaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    34 / 89 (38.20%)
    44 / 125 (35.20%)
         occurrences all number
    42
    62
    Neutropenia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    10 / 89 (11.24%)
    13 / 125 (10.40%)
         occurrences all number
    12
    22
    Eye disorders
    Dry eye
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    17 / 89 (19.10%)
    30 / 125 (24.00%)
         occurrences all number
    19
    32
    Lacrimation increased
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    12 / 89 (13.48%)
    21 / 125 (16.80%)
         occurrences all number
    14
    25
    Punctate keratitis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    3 / 89 (3.37%)
    9 / 125 (7.20%)
         occurrences all number
    3
    9
    Vision blurred
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    20 / 125 (16.00%)
         occurrences all number
    10
    25
    Blepharitis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    3 / 89 (3.37%)
    8 / 125 (6.40%)
         occurrences all number
    3
    9
    Gastrointestinal disorders
    Abdominal distension
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    7 / 89 (7.87%)
    4 / 125 (3.20%)
         occurrences all number
    8
    4
    Abdominal pain
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    23 / 125 (18.40%)
         occurrences all number
    8
    26
    Abdominal pain upper
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    6 / 125 (4.80%)
         occurrences all number
    7
    6
    Constipation
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    19 / 89 (21.35%)
    35 / 125 (28.00%)
         occurrences all number
    26
    41
    Diarrhoea
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    30 / 89 (33.71%)
    52 / 125 (41.60%)
         occurrences all number
    52
    73
    Dry mouth
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    8 / 89 (8.99%)
    11 / 125 (8.80%)
         occurrences all number
    10
    11
    Dysphagia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    2 / 89 (2.25%)
    7 / 125 (5.60%)
         occurrences all number
    3
    7
    Gastrooesophageal reflux disease
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    9 / 125 (7.20%)
         occurrences all number
    5
    9
    Nausea
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    26 / 89 (29.21%)
    56 / 125 (44.80%)
         occurrences all number
    35
    68
    Stomatitis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    10 / 125 (8.00%)
         occurrences all number
    7
    11
    Vomiting
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    11 / 89 (12.36%)
    24 / 125 (19.20%)
         occurrences all number
    13
    36
    Skin and subcutaneous tissue disorders
    Dry skin
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    18 / 89 (20.22%)
    35 / 125 (28.00%)
         occurrences all number
    20
    38
    Alopecia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    48 / 89 (53.93%)
    64 / 125 (51.20%)
         occurrences all number
    49
    67
    Rash maculo-papular
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    28 / 89 (31.46%)
    29 / 125 (23.20%)
         occurrences all number
    40
    45
    Rash macular
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    6 / 125 (4.80%)
         occurrences all number
    8
    7
    Rash erythematous
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    15 / 125 (12.00%)
         occurrences all number
    10
    16
    Pruritus
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    31 / 89 (34.83%)
    34 / 125 (27.20%)
         occurrences all number
    37
    41
    Skin hyperpigmentation
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    4 / 89 (4.49%)
    13 / 125 (10.40%)
         occurrences all number
    4
    14
    Skin exfoliation
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    3 / 89 (3.37%)
    7 / 125 (5.60%)
         occurrences all number
    4
    10
    Renal and urinary disorders
    Pollakiuria
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    4 / 125 (3.20%)
         occurrences all number
    5
    4
    Acute kidney injury
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    4 / 125 (3.20%)
         occurrences all number
    6
    4
    Dysuria
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    6 / 125 (4.80%)
         occurrences all number
    6
    6
    Haematuria
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    10 / 89 (11.24%)
    10 / 125 (8.00%)
         occurrences all number
    11
    13
    Musculoskeletal and connective tissue disorders
    Back pain
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    4 / 89 (4.49%)
    21 / 125 (16.80%)
         occurrences all number
    4
    22
    Arthralgia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    8 / 89 (8.99%)
    14 / 125 (11.20%)
         occurrences all number
    10
    16
    Pain in extremity
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    10 / 89 (11.24%)
    14 / 125 (11.20%)
         occurrences all number
    10
    16
    Myalgia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    9 / 125 (7.20%)
         occurrences all number
    6
    11
    Muscular weakness
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    8 / 89 (8.99%)
    10 / 125 (8.00%)
         occurrences all number
    10
    12
    Infections and infestations
    Oral candidiasis
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    7 / 125 (5.60%)
         occurrences all number
    5
    7
    Urinary tract infection
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    13 / 89 (14.61%)
    18 / 125 (14.40%)
         occurrences all number
    17
    23
    Metabolism and nutrition disorders
    Decreased appetite
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    35 / 89 (39.33%)
    64 / 125 (51.20%)
         occurrences all number
    43
    81
    Dehydration
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    10 / 89 (11.24%)
    12 / 125 (9.60%)
         occurrences all number
    11
    14
    Hypercalcaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    2 / 125 (1.60%)
         occurrences all number
    6
    2
    Hyperglycaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    12 / 89 (13.48%)
    17 / 125 (13.60%)
         occurrences all number
    13
    20
    Hyperkalaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    2 / 125 (1.60%)
         occurrences all number
    8
    2
    Hyperuricaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    4 / 89 (4.49%)
    8 / 125 (6.40%)
         occurrences all number
    4
    14
    Hypoalbuminaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    4 / 125 (3.20%)
         occurrences all number
    6
    4
    Hypokalaemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    6 / 89 (6.74%)
    16 / 125 (12.80%)
         occurrences all number
    7
    20
    Hyponatraemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    9 / 89 (10.11%)
    15 / 125 (12.00%)
         occurrences all number
    12
    17
    Hypophosphataemia
    alternative dictionary used: MedDRA 26.0
         subjects affected / exposed
    5 / 89 (5.62%)
    8 / 125 (6.40%)
         occurrences all number
    5
    11

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    14 Nov 2017
    Amendment 1: Added Management of Hyperglycemia section as follows: Investigators should monitor blood glucose levels and are advised to perform additional assessments if any symptoms of hyperglycemia are observed, including a thorough evaluation for infection. In addition, if steroids are used to treat any other condition, blood glucose levels may require additional monitoring. If elevated blood glucose levels are observed, patients should be treated according to local standard of care and referral to endocrinology may be considered. Patients, especially those with a history of or ongoing diabetes mellitus or hyperglycemia, should be advised to immediately notify their physician if their glucose level becomes difficult to control or if they experience symptoms suggestive of hyperglycemia such as frequent urination, increased thirst, blurred vision, fatigue, and headache. Patients who enter the study with an elevated HbA1c (≥6.5%) at baseline should be referred to an appropriate provider during Cycle 1 for glucose management. Blood glucose should be checked prior to each dosing and dose should be withheld for blood glucose >250 ml/dL (Grade 3 or higher). Dosing may continue once the patient’s blood glucose has improved to ≤ Grade 2 and patient is clinically and metabolically stable.
    13 Feb 2018
    Amendment 2: Added Cycle 6 (±1 week) slit lamp examinations for at least the first 60 enrolled patients. Clarified that end of treatment (EOT) slit lamp exams will be performed for all patients who experience a corneal adverse event on study.
    13 Apr 2018
    Amendment 3: Added text regarding drug administration setting as follows: The patient should be observed during administration of enfortumab vedotin and for at least 60 minutes following the infusion during the first 3 cycles. All supportive measures consistent with optimal subject care should be given throughout the study according to institutional standards.
    16 Apr 2018
    Amendment 4: Revised primary objective as follows: To determine the antitumor activity of singleagent enfortumab vedotin as measured by confirmed objective response rate (ORR) in patients with locally advanced or metastatic urothelial cancer who tohave previously received systemic therapy with a CPI and either previously received platinum-containing chemotherapy or are platinum-naïve and cisplatin-ineligible

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 22:33:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA